Circumventing Imatinib resistance in CML: Novel Telmisartan-based cell death modulators with improved activity and

Maximilian Gebhart1, Mostafa Alilou2, Ronald Gust1

  • 1Department of Pharmaceutical Chemistry, Institute of Pharmacy, University of Innsbruck, CCB-Centrum for Chemistry and Biomedicine, Innrain 80-82, 6020 Innsbruck, Austria.

Insights

New drug derivatives based on Telmisartan effectively resensitize Imatinib-resistant chronic myeloid leukemia (CML) cells. These compounds enhance tyrosine kinase inhibitor (TKI) therapy efficacy by overcoming drug resistance, offering a promising strategy for CML treatment.

Area of Science:

  • Medicinal Chemistry
  • Oncology
  • Pharmacology

Background:

  • Drug resistance is a major hurdle in cancer therapy, particularly in chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) like Imatinib.
  • While Imatinib has revolutionized CML treatment, a significant number of patients do not achieve long-term complete remission due to resistance.
  • Developing novel therapeutic strategies to target TKI-resistant CML cells is crucial for improving patient outcomes.

Purpose of the Study:

  • To synthesize and evaluate novel derivatives of the Telmisartan core structure (LEAD) to enhance Imatinib efficacy against TKI-resistant CML cells.
  • To improve the metabolic stability of previously identified LEAD-acid (4) methyl ester (3a) through structural modifications.
  • To assess the sensitizing potential of these new LEAD derivatives on Imatinib-resistant CML cells.

Main Methods:

  • Synthesis of various LEAD-esters (3a-h) with modified alkyl chains and aromatic groups, and bioisosteric LEAD-amides (5a-h).
  • Assessment of hydrolytic stability against esterases and amidases in vitro.
  • Evaluation of the sensitizing effect of LEAD derivatives on Imatinib-resistant KD225 (K562-resistant) CML cells using half-maximal sensitizing concentration (SC50) assays.

Main Results:

  • LEAD-amides (5a-h) exhibited high stability against esterases, with minimal cleavage by amidases for short alkyl chains.
  • LEAD-alkylesters (3a-d) were hydrolyzed by esterases (t½ = 55-82 min), while branched and aromatic esters showed increased stability (t½ up to 360 min).
  • LEAD derivatives (esters and amides) were non-cytotoxic and effectively sensitized Imatinib-resistant CML cells, with SC50 values ranging from 1.3-11.2 μM.

Conclusions:

  • Structural modifications significantly enhanced the stability of LEAD derivatives, with aromatic substitutions providing the greatest stability.
  • Intact LEAD-esters and LEAD-amides are responsible for the observed biological effects, accumulating effectively within cells.
  • These novel LEAD derivatives represent a promising strategy to overcome Imatinib resistance in CML by sensitizing resistant cells to TKI therapy.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.8K